Capricor Therapeutics Inc (CAPR)
Capricor Therapeutics Inc (CAPR) is a biotechnology company focused on developing cell-based therapeutics for rare and significant diseases, particularly in the areas of cardiology and other unmet medical needs. The company's primary focus is on regenerative medicine, utilizing its proprietary cell therapy platform to develop treatments aimed at repairing and regenerating damaged tissues.
Company News
Capricor Therapeutics met with the FDA to discuss regulatory approval for Deramiocel, its investigational cell therapy for Duchenne muscular dystrophy. The FDA provided clarity on the approval process and showed flexibility in reviewing trial data, causing the stock to surge.
Capricor Therapeutics received a Complete Response Letter from the FDA denying its Biologics License Application for deramiocel, causing a significant stock price drop and triggering a potential securities class action lawsuit.
Pfizer's (PFE) phase III study, CIFFREO, fails to show improvement in motor function in ambulatory boys with DMD treated with its gene therapy fordadistrogene movaparvovec compared to placebo.
5 hot penny stocks to watch after big news. The post 5 Hot Penny Stocks To Watch After Big News Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.